Document is current
Any future updates will be listed below
-
Authors
Poddubnyy, Denis https://orcid.org/0000-0002-4537-6015
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
- License Information
-
More Information
Article History
First Online: 23 April 2025
Competing interests
: D.P. has received research support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB; consulting fees from AbbVie, Eli Lilly, Greywolf Therapeutics, Janssen, Merk, Moonlake, Novartis, Pfizer and UCB; and speaker fees from AbbVie, Canon, Eli Lilly, Janssen, Medscape, Novartis, Peervoice, Pfizer and UCB. D.P. is a member of the executive committee of ASAS. X.B. has received research support from Abbvie, Celltrion, Janssen, Moonlake and Novartis; and consulting fees from Abbvie, Advanz, Alexion, Alphasigma, Amgen, BMS, Cesas, Celltrion, Clarivate, Galapagos, J&J, Lilly, Moonlake, Novartis, Peervoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB and Zuellig. X.B. is past president of ASAS and president-elect of EULAR.
